- Home
- CHWM vs OKYO Comparison
CHWM vs OKYO Comparison
Compare CHWM & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHWM | OKYO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.0M | 78.2M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHWM | OKYO |
|---|---|---|
| Price | $5.62 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 13.1K | ★ 43.7K |
| Earning Date | N/A | 07-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.36 | $1.26 |
| 52 Week High | $5.75 | $3.20 |
Technical Indicators
Market Signals| Indicator | CHWM | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 49.10 |
| Support Level | $4.76 | $1.31 |
| Resistance Level | $5.62 | $1.71 |
| Average True Range (ATR) | 0.45 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 38.64 | 21.44 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.